Every person’s cancer is different. Between all of the lung cancer treatment options available, how can you and your treatment team identify the best path for your individual case? Enter: comprehensive biomarker testing. Comprehensive biomarker testing (also called molecular [...]
Written by Jeff's wife, Rhonda: "Jeff was a firefighter/paramedic and a farmer and had no known risk factors for developing lung cancer. In the fall of 2015, my husband Jeff was diagnosed with stage 4 ALK-positive lung cancer that [...]
On August 15, 2019 the U.S. Food and Drug Administration approved Rozlytrek (entrectinib) for the treatment of patients with ROS1-positive, metastatic non-small cell lung cancer. It was also simultaneously approved for the treatment of patients with any solid tumor [...]
Tuesday, October 30, 2018 – Today the Food and Drug Administration (FDA) approved immunotherapy drug, pembrolizumab, also known as KEYTRUDA, in combination with chemotherapies, carboplatin, and either paclitaxel or nab-paclitaxel as a first-line treatment for patients with metastatic squamous [...]
Friday, September 28, 2018 – Today the Food and Drug Administration approved VIZIMPRO tablets (dacomitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with an EGFR (epidermal growth factor receptor) mutation. Approval was based [...]
Tuesday, January 16, 2018 – The FDA expanded approval of Gilotrif (afatinib), a first-line treatment for patients with non-small cell lung carcinoma (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-positive. Patients with lung cancers with EGFR S768I, L861Q [...]
By Jennifer C. King, PhD, Director of Science & Research at Lung Cancer Alliance Research on the treatment of lung cancer has been moving quickly and 2017 was no different. Precision medicine was a key theme this year - [...]
Monday, November 6, 2017 - The United States Food and Drug Administration (FDA) approved Alecensa (alectinib) as a first treatment for advanced non-small cell lung cancer that is positive for a biomarker called ALK. Alecensa was already approved for [...]